Share this :



Post on twitter:

 

ArcticDX licenses genes for cancer test

 
Licensing the cancer gene

Licensing the cancer gene

An international team of researchers in colorectal cancer published the results of a study that links specific genes to the risk of colorectal cancer in this week’s Nature Genetics. The study examined genetic markers in people from four countries and found that 10 of the genes studied can be linked to colorectal cancer. Together, these genes could predict up to a six-fold increase in the lifetime risk of developing colorectal cancer.

MaRS tenant ArcticDx has licensed these 10 genes to develop a screening test kit for colorectal cancer. ArctixDx is also pursuing licensing deals with other international research centres focusing on colorectal cancer and age-related macular degeneration.

This is a positive example of collaboration between academic research organizations and an Ontario-based startup company, which we hope to see turn into a technology commercialization success story.

Read more:

Related Blogs

Tags: , , , , , , , ,

  • http://www.ghbn-blog.blogspot.com Justin

    This is actually really great news. Its a tiring scene seeing Canadian innovations commercialize in the United States time and time again.

    An example is the Zenn cars:
    “ZENN Cars (stands for Zero Emission No Noise) is a Canadian company with a line of plug-in electric vehicles that cost less than $15,000. In many states there are no sales taxes and tax credits may be available. They are available today. Zenncars.com has a list of dealers accessible across the US. Just enter a zip to find the nearest one. These vehicles may only make sense for a small number of drivers as they are currently limited to less than 30 miles per charge and cannot go faster than about 25 mph. For some people, businesses, or government offices, they could make a lot of sense. With gas prices expected to average more than $3.40 per gallons, ZENN could make sense for many American families as a second or even third car. ZENN’s CEO is on a path, however, to offer a full range of electric vehicles that could satisfy many many more consumers.” (source: http://www.alternativeenergy.com/profiles/blog/show?id=1066929%3ABlogPost%3A18988)

    However, now we see facilities like Therapure Biopharma (www.therapurebio.com) in Mississauga where we have the ability to do small scale lab work for R&D, and with the same facility, be able to do large scale commercial production of products rather than shipping our innovations to the states.

    I think we are truly on our way to creating our niche of technology and science here in Southern Ontario.

George Botos @ MaRS

George Botos @ MaRS

George is a Schulich MBA student working at MaRS as a Market Research Analyst in Healthcare/Biotech for the Market Readiness Program.

 
 
Get More From MaRS   MaRS NEWSLETTERS
Facebook Twitter Vimeo Flickr

MaRS Charitable Registration Number
876682717 RR0001

Please enter your email address to subscribe to our newsletter